The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

OSU researchers find three-drug combo boosts immune system in stem cell transplantation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A three-drug combination could help patients with aggressive forms of blood cancer achieve longer cancer remission after undergoing allogeneic stem cell transplantation, according to preliminary clinical trial results presented by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Cedars-Sinai Cancer Stem Cell Transplant and Cellular Therapy Program receives expanded accreditation, top ranking for survival rates

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recognized with official accreditation for CAR T-cell therapy from the Foundation for the Accreditation of Cellular Therapy, an international accrediting body. The program was also ranked among the top adult bone marrow transplant programs in the U.S. for a third year.
Table of Contents

Login

Looking for IP Login?